New Therapeutic Options for Newly Diagnosed Multiple Myeloma Patients

	Tweet

Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy—a first step therapy designed to reduce cancer cells numbers—with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy. The findings were reported by Craig B. Reeder, M.D., at the American Society of Hematology’s annual meeting.

“For newly diagnosed multiple myeloma patients, this new treatment provides a more frequent, rapid and deeper response when compared to earlier treatment options,” says Dr. Reeder, a Mayo Clinic Cancer Center hematologist/oncologist and lead investigator of the study.

“This is the first time we have studied this treatment in newly diagnosed patients with this condition. Compared with past therapies, this new treatment proved to be very successful.”

The team studied 30 patients receiving Cybor-D in the trial. As a relevant contemporaneous control for speed and depth of response, researchers compared 34 patients treated on a recent Mayo Clinic trial of L-Dex. The findings showed that Cybor-D produced a rapid initial decline and percentage reduction in M protein (abnormal protein present in blood of myeloma patients) and a significantly higher rate of good or complete responses than L-Dex. Prophylactic use of acyclovir, a quinolone and antifungal prophylaxis was highly recommended for all patients on the study.

Other Mayo Clinic researchers contributing to the study included Rafael Fonseca, M.D.; Leif Bergsagel, M.D.; S. Vincent Rajkumar, M.D.; Jacy Boesiger; Christine Chen; Martha Lacy, M.D.; Keith Stewart, M.B.Ch.B.; Joseph Hentz and Nicholas Pirooz. Researchers from Princess Margaret Hospital in Toronto, Ontario, also contributed to the study.

Multiple Myeloma
Multiple myeloma, also called myeloma, is an incurable plasma cell (white blood cells in bone marrow) cancer. The disease’s cause is unknown. The American Cancer Society reports that nearly 20,000 people will have been diagnosed with myeloma in 2007 alone. Myeloma interferes with bone marrow function and the immune system, and can cause bone erosion, anemia, infection and possibly kidney failure.

For more information on hematology research at Mayo Clinic Cancer Center, visit http:// mayoresearch.mayo.edu/mayo/research/hematologic_malignancies.

Source: Mayo Clinic

RELATED STORIES:
Disparities among patients with extremity soft-tissue sarcomas   Long-term therapy in the fight against multiple myeloma   Smarter use of existing treatment helps dramatically boost survival of young AML patients   Drug That Modifies Gene Activity Could Help Some Older Leukemia Patients   X-rays linked to increased childhood leukemia risk   Key Gene Link to Acute Myeloid Leukemia Found   Celgene drug boosts multiple myeloma survival   New Recommendations for Use of Bisphosphonates in Treatment of Multiple Myeloma   Drug Fights Multiple Myeloma by Putting “Brakes” on Cell Proliferation   Researchers Seek Alternative for Leukemia Patients Resistant to Standard Therapies   Formaldehyde raises risk of deadly cancers: study   Anemic Children with Cancer Benefit from Erythropoietin   On the Forefront of the Fight Against Multiple Myeloma   China scientists show how arsenic treats blood cancer   Researchers discover genetic differences between lethal and treatable forms of leukemia   Exercise Benefits Leukemia Patients   Researchers Unlock Mystery of Very Aggressive Leukemia   HK scientists uncover workings behind leukemia   Mouse Mimics Chronic Leukemia, Will Aid Drug Development   Dasatinib offers new options for leukemia patients   Burkitt lymphoma gene expression signature identified   Drug combination shows promise for newly diagnosed blood cancer patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]